肿瘤

订阅

MedSci主页 / 所有栏目 / 肿瘤

2022CSCO：殷永梅教授：HER-2阳性乳腺癌诊疗指南3大更新要点

2022-04-23 杭州市肿瘤医院 倪丽伟 MedSci原创

乳腺癌2022CSCO
关注

最新HER-2阳性乳腺癌指南！看看指南怎么说。

乳腺癌是严重威胁全世界女性健康的第一大恶性肿瘤，乳腺癌患者中约80%为HR阳性。

 

4月23日，备受瞩目的2022CSCO指南大会隆重开幕。来自全国各肿瘤领域的专家和学者云端齐聚，开启了对紧跟前沿肿瘤研究和中国临床诊疗现状的CSCO系列指南的权威更新发布、解读和研讨之旅，共同推动肿瘤规范化诊疗。根据疫情防控要求，本次会议改为线上形式举办。

 

新版指南基于循证医学证据，兼顾诊疗产品的可及性，为中国乳腺癌诊疗提供规范化诊疗意见。本文由江苏省人民医院殷咏梅教授详细讲解HER-2阳性乳腺癌诊疗指南中新辅助治疗、辅助治疗以及HER-2阳性复发转移性乳腺癌治疗的更新要点。

 

1、HER-2阳性乳腺癌新辅助治疗

 

图片

图片

  

2、HER-2阳性乳腺癌辅助治疗

 

图片

  

3、HER-2阳性复发转移性乳腺癌治疗

 

图片

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1218229, encodeId=78d5121822905, content=<a href='/topic/show?id=70221045206d' target=_blank style='color:#2F92EE;'>#殷永梅#</a>教授：<a href='/topic/show?id=01ee104521ac' target=_blank style='color:#2F92EE;'>#HER-2阳性乳腺癌#</a><a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104520, encryptionId=70221045206d, topicName=殷永梅), TopicDto(id=104521, encryptionId=01ee104521ac, topicName=HER-2阳性乳腺癌), TopicDto(id=23725, encryptionId=73c423e2572, topicName=乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon May 09 17:07:10 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495811, encodeId=dabc149581149, content=<a href='/topic/show?id=27eb8e1381' target=_blank style='color:#2F92EE;'>#HER-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8713, encryptionId=27eb8e1381, topicName=HER-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b8b9208832, createdName=zhu_jun9840, createdTime=Mon Apr 25 11:40:06 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213785, encodeId=49381213e859f, content=好用<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0fdb6533655, createdName=ms7000001105543453, createdTime=Sat Apr 23 23:46:18 CST 2022, time=2022-04-23, status=1, ipAttribution=)]
    2022-05-09 病毒猎手

    #殷永梅#教授：#HER-2阳性乳腺癌##乳腺癌#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1218229, encodeId=78d5121822905, content=<a href='/topic/show?id=70221045206d' target=_blank style='color:#2F92EE;'>#殷永梅#</a>教授：<a href='/topic/show?id=01ee104521ac' target=_blank style='color:#2F92EE;'>#HER-2阳性乳腺癌#</a><a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104520, encryptionId=70221045206d, topicName=殷永梅), TopicDto(id=104521, encryptionId=01ee104521ac, topicName=HER-2阳性乳腺癌), TopicDto(id=23725, encryptionId=73c423e2572, topicName=乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon May 09 17:07:10 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495811, encodeId=dabc149581149, content=<a href='/topic/show?id=27eb8e1381' target=_blank style='color:#2F92EE;'>#HER-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8713, encryptionId=27eb8e1381, topicName=HER-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b8b9208832, createdName=zhu_jun9840, createdTime=Mon Apr 25 11:40:06 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213785, encodeId=49381213e859f, content=好用<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0fdb6533655, createdName=ms7000001105543453, createdTime=Sat Apr 23 23:46:18 CST 2022, time=2022-04-23, status=1, ipAttribution=)]
    2022-04-25 zhu_jun9840

    #HER-2#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1218229, encodeId=78d5121822905, content=<a href='/topic/show?id=70221045206d' target=_blank style='color:#2F92EE;'>#殷永梅#</a>教授：<a href='/topic/show?id=01ee104521ac' target=_blank style='color:#2F92EE;'>#HER-2阳性乳腺癌#</a><a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104520, encryptionId=70221045206d, topicName=殷永梅), TopicDto(id=104521, encryptionId=01ee104521ac, topicName=HER-2阳性乳腺癌), TopicDto(id=23725, encryptionId=73c423e2572, topicName=乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon May 09 17:07:10 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495811, encodeId=dabc149581149, content=<a href='/topic/show?id=27eb8e1381' target=_blank style='color:#2F92EE;'>#HER-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8713, encryptionId=27eb8e1381, topicName=HER-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b8b9208832, createdName=zhu_jun9840, createdTime=Mon Apr 25 11:40:06 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213785, encodeId=49381213e859f, content=好用<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0fdb6533655, createdName=ms7000001105543453, createdTime=Sat Apr 23 23:46:18 CST 2022, time=2022-04-23, status=1, ipAttribution=)]
    2022-04-23 ms7000001105543453

    好用#学习#

    1

    展开1条回复

相关资讯

European Radiology：MRI在预测乳腺癌患者新辅助化疗病理完全缓解的价值

现阶段，由于影像学上的早期治疗反应是预测乳腺癌pCR的一个指标，因此影像学检查在病情评估中至关重要。

Lancet Oncol：曲妥珠单抗+帕妥珠单抗±紫杉醇降级治疗HER2+/HR-早期乳腺癌

曲妥珠单抗+帕妥珠单抗±紫杉醇治疗12周后获得病理完全缓解的患者可获得很好的生存率

European Radiology：全自动乳腺超声(ABUS)成像技术在乳腺病变诊断中的应用

自动乳腺超声（ABUS）可以代替常用的手持式超声（HHUS），实现图像采集的标准化，完全覆盖整个乳腺体积，并将采集任务交给技术人员以减少人为误差。

Radiology：人工智能，为女性乳腺癌筛查“减负”！

现阶段，人工智能（AI）模型的使用可以协助临床缩短乳腺筛查的评估时间。

重磅！《2022年新版乳腺癌诊疗指南》正式发布

乳腺癌是女性常见的恶性肿瘤之一，发病率位居女性恶性肿瘤的首位，严重危害妇女的身心健康。

Nat Commun：HMMR过表达增加BRCA1相关乳腺癌患病风险

过表达HMMR可促进BRCA1相关乳腺癌的发生发展